The Intestinal Microbiota in Inflammatory Bowel Disease.
暂无分享,去创建一个
[1] H. Rafa,et al. Mucosal intestinal alteration in experimental colitis correlates with nitric oxide production by peritoneal macrophages: Effect of probiotics and prebiotics , 2012, Immunopharmacology and immunotoxicology.
[2] Sarah L. Brown,et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells , 2008, Nature.
[3] Se Jin Song,et al. The treatment-naive microbiome in new-onset Crohn's disease. , 2014, Cell host & microbe.
[4] R. Xavier,et al. Virus-Plus-Susceptibility Gene Interaction Determines Crohn's Disease Gene Atg16L1 Phenotypes in Intestine , 2010, Cell.
[5] Alastair Forbes,et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease , 2008, Nature Genetics.
[6] R. Bibiloni,et al. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. , 2006, Journal of medical microbiology.
[7] P. Bozko,et al. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? , 2013, Therapeutic advances in gastroenterology.
[8] V. Deretic,et al. Autophagy Is a Defense Mechanism Inhibiting BCG and Mycobacterium tuberculosis Survival in Infected Macrophages , 2004, Cell.
[9] R. Knight,et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns , 2010, Proceedings of the National Academy of Sciences.
[10] E. Mann,et al. Gastrointestinal infection as a trigger for inflammatory bowel disease , 2012, Current opinion in gastroenterology.
[11] Maria Karlsson,et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. , 2010, Cell host & microbe.
[12] D. Golenbock,et al. Induction of Persistent Colitis by a Human Commensal, Enterotoxigenic Bacteroides fragilis, in Wild-Type C57BL/6 Mice , 2009, Infection and Immunity.
[13] I. Martínez,et al. Long-Term Temporal Analysis of the Human Fecal Microbiota Revealed a Stable Core of Dominant Bacterial Species , 2013, PloS one.
[14] Thomas Lengauer,et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1 , 2007, Nature Genetics.
[15] M. Netea,et al. NOD2 and Toll-Like Receptors Are Nonredundant Recognition Systems of Mycobacterium tuberculosis , 2005, PLoS pathogens.
[16] R. Knight,et al. Diversity, stability and resilience of the human gut microbiota , 2012, Nature.
[17] N. Barnich,et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. , 1998, Gastroenterology.
[18] A. Gasbarrini,et al. Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study , 2010, The American Journal of Gastroenterology.
[19] M. Neurath,et al. Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF- plus IFN-gamma-producing CD4+ T cells that respond to bacterial antigens. , 1999, Journal of immunology.
[20] Antonio Gasbarrini,et al. Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection: A Systematic Review , 2014, Journal of clinical gastroenterology.
[21] Judy H. Cho,et al. A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.
[22] Rafael Bargiela,et al. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach , 2012, Gut.
[23] Judy H. Cho,et al. [Letters to Nature] , 1975, Nature.
[24] K. Fellermann,et al. Human defensins in Crohn's disease. , 2005, Chemical immunology and allergy.
[25] A. Di Leo,et al. Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? , 2014, World journal of gastrointestinal pathophysiology.
[26] P. Brigidi,et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. , 2000, Gastroenterology.
[27] A. Sher,et al. Bacteria-triggered CD4+ T Regulatory Cells Suppress Helicobacter hepaticus–induced Colitis , 2002, The Journal of experimental medicine.
[28] J. Galmiche,et al. Saccharomyces boulardii does not prevent relapse of Crohn's disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[29] Mourad Sahbatou,et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.
[30] J. Heimbach,et al. Novel probiotics and prebiotics: road to the market. , 2015, Current opinion in biotechnology.
[31] K. Gradel,et al. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. , 2009, Gastroenterology.
[32] E. Purdom,et al. Diversity of the Human Intestinal Microbial Flora , 2005, Science.
[33] M. Chamaillard,et al. Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition , 2004, The EMBO journal.
[34] R. Sartor,et al. Resident Enteric Bacteria Are Necessary for Development of Spontaneous Colitis and Immune System Activation in Interleukin-10-Deficient Mice , 1998, Infection and Immunity.
[35] David C. Wilson,et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.
[36] S. Ng,et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease , 2011, Gut.
[37] A. Forbes,et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease , 2005, Gut.
[38] P. Rutgeerts,et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum , 1991, The Lancet.
[39] E. El-Omar,et al. The role of infection in the aetiology of inflammatory bowel disease , 2010, Journal of Gastroenterology.
[40] Timothy L. Tickle,et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment , 2012, Genome Biology.
[41] B. Roe,et al. A core gut microbiome in obese and lean twins , 2008, Nature.
[42] R. Hammer,et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats , 1994, The Journal of experimental medicine.
[43] E. El-Omar,et al. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? , 2014, World journal of gastroenterology.
[44] J. Clemente,et al. Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome? , 2015, Expert review of gastroenterology & hepatology.
[45] R Balfour Sartor,et al. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. , 2004, Gastroenterology.
[46] P. Bork,et al. Richness of human gut microbiome correlates with metabolic markers , 2013, Nature.
[47] Helmut Neumann,et al. Caspase-8 regulates TNF-alpha induced epithelial necroptosis and terminal ileitis , 2011, Nature.
[48] R. Sartor,et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment , 2000, Gut.
[49] J. Rhodes,et al. The role of bacteria in the pathogenesis of inflammatory bowel disease. , 2010, Gut and liver.
[50] H. Kiyono,et al. Epithelial barrier: an interface for the cross‐communication between gut flora and immune system , 2012, Immunological reviews.
[51] Thomas Lengauer,et al. Genetic variation in DLG5 is associated with inflammatory bowel disease , 2004, Nature Genetics.
[52] J. Galán,et al. Salmonella Modulation of Host Cell Gene Expression Promotes Its Intracellular Growth , 2013, PLoS pathogens.
[53] J. Nicholson,et al. Host-Gut Microbiota Metabolic Interactions , 2012, Science.
[54] C. Josenhans,et al. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models , 2010, Nature Reviews Microbiology.
[55] K. Madsen,et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. , 1999, Gastroenterology.
[56] N. Socci,et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. , 2010, The Journal of clinical investigation.
[57] W. Michalski,et al. Mycobacterium avium subspecies paratuberculosis in children with early‐onset Crohn's disease , 2009, Inflammatory bowel diseases.
[58] S. Mazmanian,et al. A pathobiont of the microbiota balances host colonization and intestinal inflammation. , 2010, Cell host & microbe.
[59] M. Netea,et al. Mycobacterium paratuberculosis is recognized by Toll‐like receptors and NOD2 , 2007, Journal of leukocyte biology.
[60] P. Turnbaugh,et al. Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.
[61] M. Surette,et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. , 2015, Gastroenterology.
[62] S. Yamaoka,et al. Nod2, a Nod1/Apaf-1 Family Member That Is Restricted to Monocytes and Activates NF-κB* , 2001, The Journal of Biological Chemistry.
[63] C. Pothoulakis,et al. Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 up-regulation of Fas ligand. , 2007, Gastroenterology.
[64] W. Selby,et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. , 2007, Gastroenterology.
[65] M. Kamm,et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis , 2006, Gut.
[66] J. Sanderson,et al. Mycobacterium paratuberculosis DNA in Crohn's disease tissue. , 1992, Gut.
[67] A. Izeta,et al. On the Prevalence of M. avium Subspecies paratuberculosis DNA in the Blood of Healthy Individuals and Patients with Inflammatory Bowel Disease , 2008, PloS one.
[68] Dan R. Littman,et al. Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria , 2009, Cell.
[69] M. Weichenthal,et al. Reduced Paneth cell α-defensins in ileal Crohn's disease , 2005 .
[70] P. Mannon,et al. The fundamental basis of inflammatory bowel disease. , 2007, The Journal of clinical investigation.
[71] A. Kostic,et al. The microbiome in inflammatory bowel disease: current status and the future ahead. , 2014, Gastroenterology.
[72] R. Sartor,et al. Helicobacter hepaticus Does Not Induce or Potentiate Colitis in Interleukin-10-Deficient Mice , 2000, Infection and Immunity.
[73] N. Pace,et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases , 2007, Proceedings of the National Academy of Sciences.
[74] M. Dave,et al. The human gut microbiome: current knowledge, challenges, and future directions. , 2012, Translational research : the journal of laboratory and clinical medicine.
[75] J. Clemente,et al. Human gut microbiome viewed across age and geography , 2012, Nature.
[76] Y. Belkaid,et al. Effector and memory T cell responses to commensal bacteria. , 2013, Trends in immunology.
[77] Sang-Uk Seo,et al. Role of the gut microbiota in immunity and inflammatory disease , 2013, Nature Reviews Immunology.
[78] J. Blanco,et al. Molecular diversity of Escherichia coli in the human gut: New ecological evidence supporting the role of adherent‐invasive E. coli (AIEC) in Crohn's disease , 2009, Inflammatory bowel diseases.
[79] C. Prantera,et al. Antibiotics and Inflammatory Bowel Diseases , 2013, Digestive Diseases.
[80] M. Neurath,et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation , 2007, Nature.
[81] A. Izeta,et al. Lactase persistence, NOD2 status and Mycobacterium avium subsp. paratuberculosis infection associations to Inflammatory Bowel Disease , 2012, Gut Pathogens.
[82] Julian Parkhill,et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease , 2011, BMC Microbiology.
[83] C. Huttenhower,et al. Inflammatory bowel disease as a model for translating the microbiome. , 2014, Immunity.
[84] P. Bork,et al. A human gut microbial gene catalogue established by metagenomic sequencing , 2010, Nature.
[85] D. Fan,et al. Fecal microbiota transplantation through mid‐gut for refractory Crohn's disease: Safety, feasibility, and efficacy trial results , 2015, Journal of gastroenterology and hepatology.
[86] Tomas Hrncir,et al. Nod2 is required for the regulation of commensal microbiota in the intestine , 2009, Proceedings of the National Academy of Sciences.
[87] K. Plein,et al. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea--a pilot study. , 1993, Zeitschrift fur Gastroenterologie.
[88] S. Dalal,et al. The microbial basis of inflammatory bowel diseases. , 2014, The Journal of clinical investigation.
[89] A. Sood,et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[90] P. Brigidi,et al. Prophylaxis of pouchitis onset with probiotic therapy: A double‐blind, placebo‐controlled trial , 2000, Gastroenterology.
[91] T. Matsui,et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease , 2012, Journal of Gastroenterology.
[92] Aristides G. Eliopoulos,et al. The gut microbiota in mouse models of inflammatory bowel disease , 2014, Front. Cell. Infect. Microbiol..
[93] K. Taylor,et al. Genome-Wide Association , 2007, Diabetes.
[94] E. Zoetendal,et al. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. , 2015, Gastroenterology.
[95] Wendy S. Garrett,et al. Communicable Ulcerative Colitis Induced by T-bet Deficiency in the Innate Immune System , 2007, Cell.
[96] C. Obled,et al. Oligosaccharides isolated from goat milk reduce intestinal inflammation in a rat model of dextran sodium sulfate-induced colitis. , 2006, Clinical nutrition.
[97] C. Manichanh,et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach , 2005, Gut.
[98] James P. Nataro,et al. Diarrheagenic Escherichia coli , 1998, Clinical Microbiology Reviews.
[99] J. Ward,et al. Inflammatory large bowel disease in immunodeficient mice naturally infected with Helicobacter hepaticus. , 1996, Laboratory animal science.
[100] E. Zoetendal,et al. Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. , 2015, World journal of gastroenterology.
[101] J. Valentine,et al. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease , 2004, The Lancet.
[102] M. Trauner,et al. Temporal Bacterial Community Dynamics Vary Among Ulcerative Colitis Patients After Fecal Microbiota Transplantation , 2013, The American Journal of Gastroenterology.
[103] F. Shanahan,et al. Role of interleukin (IL‐10) in probiotic‐mediated immune modulation: an assessment in wild‐type and IL‐10 knock‐out mice , 2006, Clinical and experimental immunology.
[104] Zhang Sb,et al. Analysis of the c- kit gene in patients with slow transit constipation , 2005 .
[105] C. Neut,et al. Dysbiosis as a prerequisite for IBD. , 2004, Gut.
[106] Daniel B. DiGiulio,et al. Development of the Human Infant Intestinal Microbiota , 2007, PLoS biology.
[107] J M Ward,et al. Helicobacter hepaticus Triggers Colitis in Specific-Pathogen-Free Interleukin-10 (IL-10)-Deficient Mice through an IL-12- and Gamma Interferon-Dependent Mechanism , 1998, Infection and Immunity.
[108] J. Clemente,et al. The Long-Term Stability of the Human Gut Microbiota , 2013 .
[109] H A Malchow,et al. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? , 1997, Journal of clinical gastroenterology.
[110] A. Franke,et al. The genetics of Crohn’s disease and ulcerative colitis – status quo and beyond , 2015, Scandinavian journal of gastroenterology.
[111] J. Harel,et al. Adherent and Invasive Escherichia coli Is Associated with Granulomatous Colitis in Boxer Dogs , 2006, Infection and Immunity.
[112] S. Mazmanian,et al. Microbial learning lessons: SFB educate the immune system. , 2014, Immunity.
[113] P. Testoni,et al. Saccharomyces boulardii in Maintenance Treatment of Crohn’s Disease , 2000, Digestive Diseases and Sciences.
[114] L. T. Angenent,et al. Succession of microbial consortia in the developing infant gut microbiome , 2010, Proceedings of the National Academy of Sciences.
[115] G. Eberl. A new vision of immunity: homeostasis of the superorganism , 2010, Mucosal Immunology.
[116] S. Nikfar,et al. A Meta-Analysis on the Efficacy of Probiotics for Maintenance of Remission and Prevention of Clinical and Endoscopic Relapse in Crohn’s Disease , 2008, Digestive Diseases and Sciences.
[117] E. Cario. Commensal-Innate Immune Miscommunication in IBD Pathogenesis , 2012, Digestive Diseases.
[118] P. Rosenstiel,et al. Towards a molecular risk map--recent advances on the etiology of inflammatory bowel disease. , 2009, Seminars in immunology.
[119] Robin C. Friedman,et al. Growth and host interaction of mouse segmented filamentous bacteria in vitro , 2015, Nature.
[120] Michael D. George,et al. The cytokine IL-22 promotes pathogen colonization by suppressing related commensal bacteria. , 2014, Immunity.
[121] R. Burcelin,et al. Intestinal MicrobiOMICS to define health and disease in human and mice. , 2012, Current pharmaceutical biotechnology.
[122] Dawn B. Beaulieu,et al. Impact of Clostridium difficile on inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[123] John Penders,et al. Probiotics in the Management of Inflammatory Bowel Disease , 2012, Drugs.
[124] U. Navaneethan,et al. Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. , 2010, World journal of gastroenterology.
[125] R. Sartor,et al. Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(epsilon26) mice. , 2001, Gastroenterology.
[126] J. Doré,et al. Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray , 2010, Inflammatory bowel diseases.
[127] M. Kamm,et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis , 2003, Gut.
[128] D. Rubin,et al. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. , 2014, Journal of Crohn's & colitis.
[129] Tomohiro Watanabe,et al. NOD2 is a negative regulator of Toll-like receptor 2–mediated T helper type 1 responses , 2004, Nature Immunology.
[130] R. Sartor,et al. Lactobacillus plantarum 299V in the Treatment and Prevention of Spontaneous Colitis in Interleukin-10-Deficient Mice , 2002, Inflammatory bowel diseases.
[131] R. Hammer,et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. , 1996, The Journal of clinical investigation.
[132] David M Richards,et al. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease , 2014, Clinical and experimental gastroenterology.
[133] M. Neurath,et al. Mouse models of inflammatory bowel disease. , 2007, Advanced drug delivery reviews.
[134] P. Bork,et al. Enterotypes of the human gut microbiome , 2011, Nature.
[135] Ajay S. Gulati,et al. Inflammatory Bowel Diseases Phenotype, C. difficile and NOD2 Genotype Are Associated with Shifts in Human Ileum Associated Microbial Composition , 2012, PloS one.
[136] K. Lundin,et al. Isolation of Mycobacterium avium Subspecies paratuberculosis Reactive CD4 T Cells from Intestinal Biopsies of Crohn's Disease Patients , 2009, PloS one.
[137] M. Comalada,et al. Preventative Effects of Lactulose in the Trinitrobenzenesulphonic Acid Model of Rat Colitis , 2005, Inflammatory bowel diseases.
[138] Ellen S Pierce,et al. C O M M E N T a R Y Open Access , 2022 .
[139] N. Pace,et al. Disease phenotype and genotype are associated with shifts in intestinal‐associated microbiota in inflammatory bowel diseases , 2011, Inflammatory bowel diseases.